Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2004 2
2005 3
2006 1
2007 3
2008 6
2009 8
2010 10
2011 14
2012 14
2013 15
2014 8
2015 11
2016 12
2017 9
2018 11
2019 8
2020 19
2021 10
2022 13
2023 11
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

175 results

Results by year

Filters applied: . Clear all
Page 1
Molecular mimicry and cancer vaccine development.
Tagliamonte M, Cavalluzzo B, Mauriello A, Ragone C, Buonaguro FM, Tornesello ML, Buonaguro L. Tagliamonte M, et al. Among authors: buonaguro l. Mol Cancer. 2023 Apr 26;22(1):75. doi: 10.1186/s12943-023-01776-0. Mol Cancer. 2023. PMID: 37101139 Free PMC article. Review.
Microorganisms-derived antigens for preventive anti-cancer vaccines.
Buonaguro L, Cavalluzzo B, Mauriello A, Ragone C, Tornesello AL, Buonaguro FM, Tornesello ML, Tagliamonte M. Buonaguro L, et al. Mol Aspects Med. 2023 Aug;92:101192. doi: 10.1016/j.mam.2023.101192. Epub 2023 Jun 7. Mol Aspects Med. 2023. PMID: 37295175 Review.
Editorial: Novel Strategies for Anti-Tumor Vaccines.
Accolla RS, Buonaguro L, Melief C, Rammensee HG, Bassani-Sternberg M. Accolla RS, et al. Among authors: buonaguro l. Front Immunol. 2020 Jan 17;10:3117. doi: 10.3389/fimmu.2019.03117. eCollection 2019. Front Immunol. 2020. PMID: 32010150 Free PMC article. No abstract available.
Peptide-based vaccine for cancer therapies.
Buonaguro L, Tagliamonte M. Buonaguro L, et al. Front Immunol. 2023 Aug 16;14:1210044. doi: 10.3389/fimmu.2023.1210044. eCollection 2023. Front Immunol. 2023. PMID: 37654484 Free PMC article. Review.
Oncolytic virus therapies.
Buonaguro FM, Tornesello ML, Izzo F, Buonaguro L. Buonaguro FM, et al. Among authors: buonaguro l. Pharm Pat Anal. 2012 Nov;1(5):621-7. doi: 10.4155/ppa.12.65. Pharm Pat Anal. 2012. PMID: 24236929 Review.
Immunotherapy in hepatocellular carcinoma.
Buonaguro L, Mauriello A, Cavalluzzo B, Petrizzo A, Tagliamonte M. Buonaguro L, et al. Ann Hepatol. 2019 Mar-Apr;18(2):291-297. doi: 10.1016/j.aohep.2019.04.003. Epub 2019 Apr 25. Ann Hepatol. 2019. PMID: 31047849 Free article. Review.
Human Hepatocellular Carcinoma (HCC).
Buonaguro L. Buonaguro L. Cancers (Basel). 2020 Dec 12;12(12):3739. doi: 10.3390/cancers12123739. Cancers (Basel). 2020. PMID: 33322652 Free PMC article.
Pathogens: Our Allies against Cancer?
Buonaguro L, Cerullo V. Buonaguro L, et al. Mol Ther. 2021 Jan 6;29(1):10-12. doi: 10.1016/j.ymthe.2020.12.005. Epub 2020 Dec 5. Mol Ther. 2021. PMID: 33308440 Free PMC article. Review. No abstract available.
Covid-19: Time for a paradigm change.
Buonaguro FM, Ascierto PA, Morse GD, Buonaguro L, Puzanov I, Tornesello ML, Bréchot C, Gallo RC. Buonaguro FM, et al. Among authors: buonaguro l. Rev Med Virol. 2020 Sep;30(5):e2134. doi: 10.1002/rmv.2134. Epub 2020 Jul 3. Rev Med Virol. 2020. PMID: 32618072 Free PMC article. No abstract available.
175 results